Advertisement.
Advertisement.
Advertisement
Advertisement.
ACXP Acurx Pharmaceuticals Inc
1,578
| Market Cap | $35.76M |
| Volume | 14,401.00 |
| 52-Wk High | $8.82 |
| 52-Wk Low | $1.17 |
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome
PR Newswire•10 days ago
USPTO Grants Acurx Pharmaceuticals New Patent for Ibezapolstat to Treat CDI While Reducing Recurrence of Infection and Improving Health of the Gut Microbiome USPTO Grants Acurx Pharmaceuticals New...
Share to Feed
Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024 Financial Results on August 9, 2024 Conference Call and Provide Business Update Acurx Pharmaceuticals, Inc. to Discuss Second Quarter 2024...
PR Newswire•11 days ago
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results for CDI at Scientific Conference Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2...
PR Newswire•12 days ago
Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase...
PR Newswire•2 months ago
Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update Acurx Pharmaceuticals, Inc. Reports First Quarter 2024 Results and Provides Business Update PR Newswire...
PR Newswire•2 months ago
Acurx Pharmaceuticals Announces Presentation of Ibezapolstat Phase 2 Clinical Trial Results at ESCMID Global 2024 Scientific Conference Acurx Pharmaceuticals Announces Presentation of Ibezapolstat...
PR Newswire•3 months ago
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference Acurx Pharmaceuticals Announces Presentation of...
PR Newswire•3 months ago
Staten Island, New York--(Newsfile Corp. - March 21, 2024) - Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the...
Newsfile Corp. - News Releases•4 months ago
Acurx Pharmaceuticals (NASDAQ:ACXP Get Free Report) had its price objective reduced by equities researchers at HC Wainwright from $14.00 to $12.00 in a report issued on Tuesday, Benzinga...
Zolmax•4 months ago
Acurx Pharmaceuticals (NASDAQ:ACXP Get Free Report) had its price target decreased by stock analysts at HC Wainwright from $14.00 to $12.00 in a research report issued on Tuesday, Benzinga...
Ticker Report•4 months ago